We are thrilled to announce that Remedium, a Boston-based preclinical-stage biotech company, has successfully oversubscribed its extension seed round of funding. This significant milestone was achieved with the backing of some of the most prestigious names in the industry, including Lifespan Ventures, Seedfolio, Wharton Alumni Angels, Ulu Ventures, and Healthspan Capital. We are gearing up for Series A!
With these esteemed partners, Remedium is now even better positioned to accelerate its groundbreaking work in the development of next-generation therapeutics. The company’s mission is centered around creating life-saving innovations, and one of the most promising of these is the Prometheus™ adjustable-dose gene therapy platform. This pioneering platform is designed to treat chronic diseases such as type 2 diabetes and obesity, conditions that affect millions of people worldwide, and represents a paradigm shift in gene therapy. Unlike traditional treatments, which often involve lifelong management of symptoms, Prometheus™ offers a novel approach that delivers therapeutic proteins with multi-year durability and zero-order pharmacokinetics, potentiating improved safety and efficacy over current generation approaches. This innovation holds the promise of vastly improving the quality of life for patients and reducing the burden on healthcare systems.
The support from new investors enables Remedium to complete their move into the newly opened Eli Lilly Gateway Laboratory incubator in the Boston Seaport, initiate a Gates Foundation collaboration for a significant pipeline expansion, and finalize multiple strategic collaborations that are in advanced discussions.
As Remedium continues to push the boundaries of what is possible in biotech, the company remains committed to its core mission: developing therapies that not only extend life but also enhance its quality. The recent funding round is a testament to the progress that has been made, and it sets the stage for exciting developments in the near future.